What is Third Pole Therapeutics?
Third Pole Therapeutics is at the forefront of developing accessible inhaled nitric oxide therapies. The company specializes in creating portable and wearable devices designed to deliver life-saving inhaled nitric oxide, aiming to enhance patient care globally. Their focus on respiratory therapies targets both healthcare providers and individuals requiring advanced treatment options. The company's commitment to advancing its technology is evident through its pursuit of strategic partnerships and ongoing clinical trials.
How much funding has Third Pole Therapeutics raised?
Third Pole Therapeutics has raised a total of $39.1M across 3 funding rounds:
Unspecified
$13.8M
Debt
$350K
Unspecified
$25M
Unspecified (2015): $13.8M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Unspecified (2022): $25M, investors not publicly disclosed
Key Investors in Third Pole Therapeutics
PPP
Public-Private Partnership
What's next for Third Pole Therapeutics?
With a major enterprise-level funding context and a recent strategic investment, Third Pole Therapeutics is poised for significant expansion. The company's focus on making inhaled nitric oxide therapies more accessible suggests a trajectory towards scaling production and broadening market reach. Future developments will likely involve further clinical validation, strategic alliances to enhance distribution, and the potential for new product iterations to address a wider range of respiratory ailments. This capital infusion is expected to accelerate their mission to improve global respiratory care.
See full Third Pole Therapeutics company page
